FREE Account Opening + No Clearing Fees
Loading...
June 16, 2023 - June 21, 2023

Vilin Bio Med IPO Review & Recommendations

Dilip Davda recommend to "Avoid" the IPO.

Vilin Bio Med IPO Review Summary from brokers and analysts

Review By Apply May Apply Neutral Avoid Not Rated
Count 0 0 0 1 0
% 0.00 0.00 0.00 100.00 0.00

Vilin Bio Med IPO Analysis By Brokers/Analysts

Reviewer Recommendation Past Reviews
Dilip Davda Avoid

Vilin Bio Med IPO Review by Dilip Davda (Avoid)

[Dilip Davda]  The company operates in a highly competitive and fragmented segment with many players around. The sudden boost in its bottom line for 9M FY23 raises eyebrows and concern over sustainability going forward. Based on such super earnings, the issue appears greedily priced, while based on its track records, it appears exorbitantly priced. There is no harm in skipping this pricey issue. Read detail review...

Vilin Bio Med IPO Peer Comparison

Vilin Bio Med Limited peer comparison with similar listed entities. () (As on March 31, 2022)

Company NameEPS (Rs)NAV (per share) (Rs)P/E (x)RoNW (%)
EPS Basic
Vilin Bio Med Limited0.048.96294.820.45
JFL Life Sciences Limited3.7742.6610.8225.20
Vaishali Pharma Limited3.8224.9933.7715.27
Anuh Pharma Limited6.106.1014.7014.30

Notes:

  1. Vilin Bio Med Limited's financial information is derived from our Restated Financial Information for the year ended March 31, 2022.
  2. All the financial information for listed industry peers mentioned above is sourced from the regulatory filings made by aforesaid companies to stock exchanges for the year ended March 31, 2022, to compute the corresponding financial ratios. Except for JFL Life Sciences Limited, which is as on February 28, 2022, derived from Final Prospectus dated August 11, 2022.
  3. P/E figures for the peers are based on closing market prices of equity shares on BSE on June 6, 2023, divided by the EPS in the table above.
  4. Basic Earnings per share = Net profit after tax, as restated attributable to equity shareholders /Weighted average number of shares outstanding during the year/ period.
  5. NAV per share for listed industry peers is computed as the Total Equity as on March 31, 2022, divided by the outstanding number of equity shares as on March 31, 2022.
  6. Return on Net Worth (%) for listed industry peers has been computed based on the Profit for the year ended March 31, 2022, divided by Total Equity as on March 31, 2022.

Vilin Bio Med IPO Review by Members

Vilin Bio Med IPO Reviews, analysis and views by popular members. Read Vilin Bio Med Limited IPO reviews by retail investors to find recommended ipo to buy.

Post Recommendation Manage Your IPO Reviews

Vilin Bio Med IPO Review Summary by Members

Review By Apply May Apply Neutral Avoid
Count 0 0 1 1
% 0.00 0.00 50.00 50.00
Clear Search
Member Review
IPO LEADER
IPO Mentor IPO Mentor (800+ Posts, 400+ Likes)

Avoid

Avoid

June 21, 2023 6:42:33 AM
hiteshhastimal

Neutral

Kya lagta hai doston

June 12, 2023 2:20:15 PM

Post Recommendation Manage Recommendations

Note:

  • The recommendations or analysis of public issues posted above expresses the views of its author and does not represent the views of Chittorgarh.com or its staff.
  • We reserve the right to remove any objectionable post without providing a reason.